irinotecan

You have access
A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results
JUNJI KAWADA, DAISUKE SAKAI, YUTAKA KIMURA, MOTOHIRO HIRAO, KAZUHIRO NISHIKAWA, NAOTOSHI SUGIMOTO, YOSHIO OKA, SHUNJI ENDO, YUTAKA ISOZAKI, JIN MATSUYAMA, RYOHEI KAWABATA, TOMONO KAWASE, KAZUMASA FUJITANI, YUKINORI KUROKAWA, HISATO KAWAKAMI, TOSHIO SHIMOKAWA, TAROH SATOH and Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)

Anticancer Research March 2025, 45 (3) 1077-1085; DOI: https://doi.org/10.21873/anticanres.17495
You have access
Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy
YAOYI ZHANG, XIAOHUI LI, SHENG LI, ZHIJIAN YANG, ROBERT M. HOFFMAN and CHEN YU

Anticancer Research January 2025, 45 (1) 399-404; DOI: https://doi.org/10.21873/anticanres.17428
You have access
Taurine Protects Irinotecan-induced Muscle Dysfunction by Modulating Oxidative Stress and Endoplasmic Reticulum Stress in Human Skeletal Muscle Cells
CHIH-I CHEN, YU-CHI CHEN, YI-KAI KAO, CHIA-HUNG CHEN, PO-WEN YANG, PIN-CHUN CHEN, LING-CHIAO SONG and KAI LUNG TSAI

Anticancer Research December 2024, 44 (12) 5371-5378; DOI: https://doi.org/10.21873/anticanres.17364
Open Access
Therapeutic Responses to Two New SN-38 Derivatives in Colorectal Cancer Patient-Derived Xenografts and Respective 3D In Vitro Cultures
KATARZYNA UNRUG-BIELAWSKA, DAVID EARNSHAW, MAGDALENA CYBULSKA-LUBAK, EWELINA KANIUGA, ZUZANNA SANDOWSKA-MARKIEWICZ, MALGORZATA STATKIEWICZ, IZABELA RUMIENCZYK, MICHALINA DĄBROWSKA, JUSTYNA KOCIK-KROL, KRZYSZTOF KLIMKIEWICZ, MAGDALENA URBANOWICZ, BEATA NAUMCZUK, LECH KOZERSKI, MARCIN KRZYKAWSKI, MICHAL MIKULA and JERZY OSTROWSKI

Anticancer Research October 2024, 44 (10) 4219-4224; DOI: https://doi.org/10.21873/anticanres.17252
You have access
Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial
YASUYOSHI SATO, HIROHARU YAMASHITA, KOICHI YAGI, SACHIYO NOMURA and YASUYUKI SETO

Anticancer Research July 2024, 44 (7) 3125-3131; DOI: https://doi.org/10.21873/anticanres.17126
Open Access
Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet
MOTOKAZU SATO, QINGHONG HAN, RYOSUKE MORI, KOHEI MIZUTA, BYUNG MO KANG, SEI MORINAGA, NORITOSHI KOBAYASHI, YASUSHI ICHIKAWA, ATSUSHI NAKAJIMA and ROBERT M. HOFFMAN

Anticancer Research April 2024, 44 (4) 1499-1504; DOI: https://doi.org/10.21873/anticanres.16946
Open Access
Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer
MOTOKAZU SATO, QINGHONG HAN, YUTARO KUBOTA, ANTON BARANOV, DANIEL ARDJMAND, KOHEI MIZUTA, SEI MORINAGA, BYUNG MO KANG, NORITOSHI KOBAYASHI, MICHAEL BOUVET, YASUSHI ICHIKAWA, ATSUSHI NAKAJIMA and ROBERT M. HOFFMAN

Anticancer Research January 2024, 44 (1) 31-35; DOI: https://doi.org/10.21873/anticanres.16785
You have access
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer
KEI HAYASHI, MITSUHIRO FURUTA, KYOKO FURUSAWA, TOMOMI HAMAGUCHI, MAMORU WATANABE, YASUHIRO INOKUCHI, SHIZUNE ONUMA, ITARU HASHIMOTO, HIDEAKI SUEMATSU, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, TAKANOBU YAMADA, AKIFUMI NOTSU, TAKASHI OGATA, TAKASHI OSHIMA, NOZOMU MACHIDA, JUNJI FURUSE and SHIN MAEDA

Anticancer Research June 2023, 43 (6) 2831-2840; DOI: https://doi.org/10.21873/anticanres.16452
You have access
Experimental Exploration for Genes Related to Susceptibility and Resistance to Irinotecan
SUGURU OGATA, TOMOYA SUDOU, FUMIHIKO FUJITA, TAKEFUMI YOSHIDA, KENICHI KOUSHI, TAKASHI NOGUCHI, JUNYA FUKUDA, NANAE OGATA, YOSHITAKA NOBUKUNI and YOSHITO AKAGI

Anticancer Research August 2022, 42 (8) 4011-4016; DOI: https://doi.org/10.21873/anticanres.15897
You have access
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII

Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745

Main menu

User menu

Search

irinotecan

Pages